LivaNova PLC (NASDAQ: LIVN) surpassed Q3 earnings expectations with adjusted EPS of $0.90 and revenue of $318.1 million, boosting its 2024 outlook. With strong gains in cardiopulmonary and neuromodulation segments, traders should watch this upward trajectory closely.